Will Stellest (orthokeratology) glasses help stabilize and decrease the progression of myopia in a 13-year-old male?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Stellest Glasses for Myopia Control in a 13-Year-Old Male

Yes, Stellest spectacle lenses (defocus incorporated multiple segments or DIMS technology) can help slow myopia progression in a 13-year-old, though the evidence provided focuses primarily on other myopia control interventions that have stronger guideline support.

Clarification on Stellest vs. Orthokeratology

Stellest glasses are spectacle lenses with defocus technology, not orthokeratology. The expanded question incorrectly conflates these two distinct interventions. Orthokeratology refers to overnight rigid contact lenses that temporarily reshape the cornea 1.

Evidence-Based Myopia Control Options

First-Line Interventions Supported by Guidelines

The American Academy of Ophthalmology recommends several interventions for slowing myopia progression in school-age children 1:

  • Multifocal contact lenses (particularly MiSight FDA-approved daily disposables) have demonstrated efficacy in slowing progression without complications during 6 years of monitoring in children 8-12 years old 2

  • Low-dose atropine (0.01-0.05%) shows the largest positive effects for slowing myopia progression, though it requires compounding pharmacies in the United States 1

  • Orthokeratology has been shown to slow myopic progression in children and adolescents, reducing axial elongation by 32-63% compared to single-vision spectacles over 2 years 1, 3

  • Multifocal spectacles are effective in slowing progression, though to a lesser degree than antimuscarinic medications 1

Optimal Combination Approach

For maximum benefit, the American Academy of Ophthalmology recommends combining low-dose atropine (0.01-0.05%) with multifocal daily disposable contact lenses (MiSight) for children who can safely handle contact lenses 2. This combination approach provides synergistic myopia control effects.

Environmental Modifications

  • Increasing outdoor time to at least 1-2 hours daily can help reduce myopia progression 2
  • This intervention has been shown to reduce the likelihood of myopia onset 1

Specific Considerations for a 13-Year-Old

At age 13, this patient falls within the age range where myopia control interventions remain effective:

  • Orthokeratology studies have included children through adolescence, with efficacy demonstrated in school-aged children 4, 3, 5
  • The treatment benefit with atropine appears stable through 15 years of age 6
  • A study specifically examining young myopic adolescents ages 11-15 years showed myopia reduction between -1.25 and -5.00 D with orthokeratology 7

Safety Profile

Contact Lens Options

  • Daily disposable contact lenses are the safest option with the lowest rate of complications for soft contact lens wear 2
  • Orthokeratology carries a risk of microbial keratitis similar to other overnight contact lens wear modalities, with particular concern for Acanthamoeba keratitis when tap water is used in care regimens 1, 2
  • Proper lens hygiene and compliance are essential for orthokeratology safety 2, 5

Atropine Safety

  • Low-dose atropine (0.01-0.05%) has fewer side effects than the 1% concentration used for amblyopia 1
  • Higher concentrations can cause photosensitivity and require careful monitoring 6

Common Pitfalls to Avoid

  • Undercorrection of myopia does not slow progression and should not be used as a control strategy 1
  • Timolol or other IOP-lowering drops have not shown efficacy in reducing myopia progression 2
  • Visual training exercises, acupuncture, and nutritional approaches lack scientific evidence of effectiveness 2
  • Maintenance of orthokeratology requires nightly lens wear in young adolescents to maintain myopia reduction 7

Duration and Monitoring

  • Most myopia reduction with orthokeratology occurs during the first 2 weeks, with 75% of possible reduction in this timeframe 7
  • Long-term studies up to 10 years have confirmed efficacy and acceptable safety 3
  • The optimal duration of treatment and potential rebound phenomenon after discontinuation remain areas requiring further research 3

Regarding Stellest Specifically

While the provided evidence does not specifically address Stellest lenses by name, they fall under the category of multifocal spectacles that incorporate defocus technology. The American Academy of Ophthalmology acknowledges multifocal spectacles as effective for myopia control, though less effective than antimuscarinic medications 1. For a 13-year-old who cannot or will not use contact lenses or atropine, Stellest glasses represent a reasonable non-invasive option for myopia control 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Slowing Pediatric High Myopia Progression with Evidence-Based Interventions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Myopia Control With Orthokeratology: A Review.

Eye & contact lens, 2022

Guideline

Atropine Eye Drops for Amblyopia and Myopia Control

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Clinical study of orthokeratology in young myopic adolescents.

International contact lens clinic (New York, N.Y.), 1999

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.